KIAA2022 CRISPR Activation Plasmid (h): sc-415544-ACT

KIAA2022 (also known as X-linked intellectual disability protein KIAA2022) encodes a large, brain-enriched protein implicated in neuronal development and synaptic function. Although its molecular partners are not fully defined, studies link KIAA2022 to regulation of neurite outgrowth, dendritic spine morphology, and activity-dependent transcriptional programs that shape neuronal connectivity. Genetic disruption or loss-of-function variants in KIAA2022 have been associated with neurodevelopmental phenotypes, including X-linked intellectual disability and autism spectrum–related features, supporting its relevance to pathways governing cortical circuit formation and excitatory/inhibitory balance. As a research target, KIAA2022 is useful for dissecting gene regulatory networks in human iPSC-derived neurons and for probing cellular processes that couple cytoskeletal dynamics to synaptic maturation.

KIAA2022 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous KIAA2022 expression without altering the underlying DNA sequence.

KIAA2022 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the KIAA2022 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the KIAA2022 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous KIAA2022 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native KIAA2022 locus and enabling the study of KIAA2022-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of KIAA2022 pathway restoration in tumor cells with silenced or reduced KIAA2022 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.